MRUS
Closed
Merus Bv
52.66
+0.06 (+0.11%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 52.6
Day's Range: 52.25 - 53.69
Send
sign up or login to leave a comment!
When Written:
18.33
Merus BV is a clinical-stage biotechnology company that focuses on developing innovative bispecific antibody therapies for cancer patients. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands. Merus BV's lead product candidate, Zenocutuzumab, is being developed for the treatment of solid tumors with NRG1 gene fusions. The company's proprietary technology platform, called Biclonics, enables the design and development of bispecific antibodies that can target multiple cancer antigens simultaneously. Merus BV has collaborations with several pharmaceutical companies, including Incyte Corporation, Eli Lilly and Company, and Ono Pharmaceutical Co., Ltd. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol MRUS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








